If you read the source article you’ll never look at constipation the same way ever again. Better dig deeper to find out why your applicant is constipated. It may not be just a horrible diet and lack of dietary fiber.
And yet another FDA approved drug to counteract adverse effects from another FDA approved drug.
The US Food and Drug Administration (FDA) has approved naloxegol (Movantik, AstraZeneca Pharmaceuticals), a peripherally acting opioid receptor antagonist, for the treatment of opioid-induced constipation (OIC) in adults with chronic noncancer pain.
OIC is a common adverse effect of opioid use. An estimated 40% to 80% of patients receiving long-term opioid therapy experience OIC, which can be severe enough to cause discontinuation of opioid therapy.